- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Journal: COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. (Pubmed Central) - Sep 2, 2020
However, a small proportion develop severe disease requiring ICU admission and prolonged ventilation, although fatal outcome is overall rare. The data also reflect the current uncertainties regarding specific treatment options, highlighting that additional data on antiviral and immunomodulatory drugs are urgently needed.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Prezcobix (darunavir/cobicistat) / Gilead, J&J
Biomarker, Review, Journal: Pharmacogenomics of COVID-19 therapies. (Pubmed Central) - Sep 1, 2020
In conclusion, although direct evidence in COVID-19 patients is lacking, we identified potential actionable genetic markers in COVID-19 therapies. Clinical studies in COVID-19 patients are deemed warranted to assess potential roles of these markers.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Characteristics of Liver Tests in COVID-19 Patients. (Pubmed Central) - Aug 29, 2020
Patients with abnormal liver tests were at higher risk of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, which should be monitored and evaluated frequently.
- |||||||||| Journal: Directly Acting Antivirals for COVID-19: Where Do We Stand? (Pubmed Central) - Aug 28, 2020
Other drugs that have been used include the nucleosidase inhibitors and polymerase acidic endonuclease inhibitors which are currently approved for prevention of influenza infections. While some of the drugs appear promising in small case series and reports, more clinical trials currently in progress are required to provide higher quality evidence.
- |||||||||| hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Journal: Cerebral Venous Thrombosis Associated with COVID-19. (Pubmed Central) - Aug 27, 2020
Severe and potentially fatal deep cerebral thrombosis may complicate the initial clinical presentation of COVID-19. We urge awareness of this atypical manifestation.
- |||||||||| Clinical, Review, Journal: Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. (Pubmed Central) - Aug 27, 2020
Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.
- |||||||||| doxycycline / Generic mfg., Pierre Fabre
Review, Journal: Potential benefits of combination of Nigella sativa and Zn supplements to treat COVID-19. (Pubmed Central) - Aug 26, 2020
In addition to these drugs, rationale and evidence have been presented to use chloroquine to treat COVID-19, arguably with certain precautions and criticism...The effectiveness of the Zn salt supplement could also be enhanced with N. sativa as its major bioactive component might work as ionophore to allow Zn2+ to enter pneumocytes - the target cell for SARSCoV-2. Given those benefits, this review paper describes how N. sativa in combination with Zn could be useful as a complement to COVID-19 treatment.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. (Pubmed Central) - Aug 26, 2020
Given the rapid pace of clinical information and discoveries, it is important for clinicians to be up to date with the latest, evidence-based treatment options available for this novel disease. Keeping up with this current pace of information, we review the clinical studies of different therapeutic options available to treat SARS-CoV-2.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. (Pubmed Central) - Aug 26, 2020
Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone...Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir...Favipiravir shows favorable results compared to other tested medications. Heparin and dexamethasone show benefit especially for severe COVID-19 cases.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Protease Inhibitor Use in COVID-19. (Pubmed Central) - Aug 26, 2020
Therefore, we have provided suggestions for the diagnosis, treatment, and prevention of the novel coronavirus pneumonia in the current epidemic situation based on the latest reports and the experience of doctors treating COVID-19 in our hospital. We recommend lopinavir/ritonavir as the effective drugs for antiviral treatment according to our experience in administering lopinavir/ritonavir to COVID-19 patients and the successful cases of these drugs in treating MERS and SARS, but need more clinical data to prove their efficacy in treating COVID-19.
- |||||||||| chloroquine phosphate / Generic mfg., hydroxychloroquine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Review, Journal: A narrative review of emerging therapeutics for COVID-19. (Pubmed Central) - Aug 26, 2020
Long-term results from large, well-designed randomized trials will provide definitive evidence of therapeutic effectiveness and are likely months away. The trial landscape for promising therapies is described.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Review, Journal: Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. (Pubmed Central) - Aug 26, 2020
In life-threatening cases of coronavirus disease 2019, the potential risks of therapy to the fetus may be more than offset by the benefit of curing the mother. Although preclinical and placental transfer studies are required for a number of potential anti-severe acute respiratory syndrome coronavirus 2 drugs, several medications can already be used in pregnant women.
- |||||||||| remdesivir / Generic mfg., chloroquine phosphate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Review, Journal: COVID-19: A review of therapeutics under investigation. (Pubmed Central) - Aug 26, 2020
Several of these therapies have been studied, but many have limited evidence behind their use, and clinical trials to evaluate their efficacy are either ongoing or have not yet begun. This review summarizes the existing evidence for medications currently under investigation for treatment of COVID-19, including remdesivir, chloroquine/hydroxychlorquine, convalescent plasma, lopinavir/ritonavir, IL-6 inhibitors, corticosteroids, and angiotensin-converting enzyme inhibitors.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, ritonavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Appraisal of Critically Ill COVID-19 Patients at a Dedicated COVID Hospital. (Pubmed Central) - Aug 24, 2020
Using binary logistic regression, elevated IL-6(0.02441), low PFR(0.00082), and endotracheal intubation(2.04E-10) were statistically significant predictors of death. "Happy Hypoxia", hyperglycemia, high inflammatory markers (IL-6, ferritin), and ARDS were hallmark of critical COVID-19, early detection of factors associated with severity and mortality and starting the multipronged management with oxygen in prone position, hydroxychloroquin, antiviral, methylprednisolone, anticoagulants, tocilizumab early may help in halting the worsening of COVID and reduce morbidity and mortality.
- |||||||||| ritonavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Review, Journal: Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits. (Pubmed Central) - Aug 24, 2020
There is discussion about the preventive efficacy of vitamin C, at the dose achievable by the diet, but recent reviews suggest that this substance can be useful in the case of strong immune system burden caused by viral disease. Computational methods and laboratory studies support the need to undertake apposite preclinical, epidemiological, and experimental studies on the potential benefits of citrus fruit components for the prevention of infectious diseases, including COVID-19.
- |||||||||| lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, PK/PD data, Journal: A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients. (Pubmed Central) - Aug 23, 2020
Use of lower than usual initial dosages for most of the above-mentioned antiretroviral drugs appears to be appropriate for Chinese patients. It was also suggested to individualize combination antiretroviral therapy regimens according to the specific physiologic and genetic characteristics of patients, not only limited to Chinese, to maintain durable efficacy, improve toxicity management, and reduce drug costs.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: COVID-19 Treatment: Close to a Cure? - A Rapid Review of Pharmacotherapies for the Novel Coronavirus. (Pubmed Central) - Aug 22, 2020
Ribavirin may be beneficial as an add-on therapy but is ineffective as monotherapy...Chloroquine and hydroxychloroquine have shown in vitro inhibition of SARS-CoV-2, and the studies on clinical efficacy and whether the benefits outweigh the risk of dysrhythmias remain inconclusive. For patients who developed cytokine release syndrome, interleukin-6 inhibitors may be beneficial.
- |||||||||| Enrollment open, Trial completion date, Trial primary completion date: THDMS-COVID19: Fight COVID-19 Trial (clinicaltrials.gov) - Aug 20, 2020
P3, N=320, Recruiting,
For patients who developed cytokine release syndrome, interleukin-6 inhibitors may be beneficial. Not yet recruiting --> Recruiting | Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Preclinical, Journal: Anti-HIV and anti-HCV drugs inhibit p-glycoprotein efflux activity in Caco-2 cells and precision-cut rat and human intestinal slices. (Pubmed Central) - Aug 20, 2020
Lopinavir, ritonavir, saquinavir, atazanavir, maraviroc, ledipasvir, and daclatasvir inhibited the efflux of a model ABCB1 substrate, rhodamine 123 (RHD123), in Caco-2 cells and rat-derived PCIS...Abacavir, zidovudine, tenofovir disoproxil fumarate, etravirine, and rilpivirine did not inhibit intestinal ABCB1...Our data help clarify the molecular mechanisms responsible for reported increases in the bioavailability of ABCB1 substrates including antivirals and drugs prescribed to treat co-morbidity. These results could help guide the selection of combination pharmacotherapies and/or suitable dosing schemes for patients infected with HIV and/or HCV.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
Journal: COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. (Pubmed Central) - Aug 18, 2020
Preventive measures (social distancing and social isolation) also increase cardiovascular risk. Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir. (Pubmed Central) - Aug 15, 2020
Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed. No abstract available
- |||||||||| tacrolimus / Generic mfg., Prezcobix (darunavir/cobicistat) / Gilead, J&J, lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19). (Pubmed Central) - Aug 14, 2020
Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction...The peculiarity of clinical presentation and the management difficulties represent the flagship of our case-report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy.
- |||||||||| Intron A (interferon α-2b) / Merck (MSD), Biogen, Actemra IV (tocilizumab) / Roche, JW Pharma, Avelox (moxifloxacin) / Bayer
[VIRTUAL] Capturing Clinician’s Experiences Repurposing Drugs to Inform Future Studies During COVID-19 () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_570;
CURE ID gives clinicians an opportunity to share their treatment experiences and discuss their questions with a global community of healthcare providers. By utilizing the CURE ID platform, in conjunction with data gathered from other registries, observational studies and clinical trials, hypotheses can be generated that may inform future clinical trials and ultimately, potentially find safe and effective treatments for this deadly disease.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Retrospective data, Review, Journal: Drug treatments for covid-19: living systematic review and network meta-analysis. (Pubmed Central) - Aug 11, 2020
Glucocorticoids probably reduce mortality and mechanical ventilation in patients with covid-19 compared with standard care. The effectiveness of most interventions is uncertain because most of the randomised controlled trials so far have been small and have important study limitations.
|
